VEGFA and neoplasm: The discovery of VEGF led to a major step forward in understanding angiogenic pathways; in 1993, Kim and colleagues identified mAbs that were able to target and neutralize VEGFA, thereby inhibiting tumor growth in preclinical studies [248].